

ADAKVEO® (crizanlizumab-tmca)

RETURN COMPLETED FORM VIA FAX TO:

Referral Form

888.898.9113

PATIENT INFORMATION (Complete or tax e.	xisting chart)	ESCRIBER INFORMATION	N	
Patient Name:	Pre	escriber Name:		
Address:		ate License:	NPI #:	
City, State, Zip:	DE	EA:	Phone:	
Phone: Alt.Phone:	Ac	ddress:	Fax:	
DOB:Gender: M F Last 4 SSN:_				
WT: HT: Allergies: INSURANCE INFORMATION - INSTEAD - ju	Co	ontact Person:	Phone:	
Primary Insurance:	RX Cai	rd (PBM):		_
City, State, Zip:	BIN:_		PCN:	-
Plan #:	City, S	itate, Zip:		_
Group #:	Group) #:		_
Phone:	Phon	e:		
DIAGNOSIS/CLINICAL INFORMATION				
D57.00 – Sickle Cell Disorders.	Other:			
LABORATORY DATA				
CBC:	BMP:		SEROLOGY:	
OTHER:				
ADAKVEO® (crizanlizumab-tmca) DOSING		REFILLS:		
Initial/Reloading and Maintenance d	ose: 5mg/kg on 0,			
2 and 6 weeks and then q 4 weeks				
Maintenance dose: 5mg/kg q 4 weel	ks			
SIGNATURE				
X		DATE:		
Prescribing Physician Signature)			
<i>v , v</i>				

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

Important Information: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.

Thank you for choosing Talis Healthcare

RETURN COMPLETED FORM VIA FAX TO: 888.898.9113